SCaBER Xenograft Model Overview

The SCaBER xenograft model is derived from a human squamous cell carcinoma of the urinary bladder and represents one of the few well-characterized models available for studying basal-squamous bladder cancer, a subtype associated with poor prognosis, high metastatic potential, and chemoresistance. The SCaBER cell line was established from a tumor in a male patient with invasive bladder cancer exhibiting squamous differentiation. Unlike conventional transitional cell carcinoma models, SCaBER captures the molecular and phenotypic features of basal urothelial tumors, including elevated EGFR expression, loss of luminal differentiation, and high proliferation rates.

In vivo, SCaBER xenografts exhibit aggressive growth kinetics and form poorly differentiated, highly cellular tumors with pronounced basal-like histopathology. This model is particularly useful for evaluating drugs targeting the EGFR/MAPK axis, investigating epithelial-to-mesenchymal transition (EMT), and exploring therapeutic resistance in squamous-transformed urothelial tumors. SCaBER is a preferred platform for studies requiring rapid tumor development, robust activation of growth factor pathways, and loss of epithelial integrity.

Request a Custom Quote for SCaBER Xenograft Model

Biological and Molecular Characteristics

SCaBER cells display a classic basal-squamous molecular phenotype, characterized by the absence of urothelial markers and the presence of basal keratins and EMT-associated proteins. The cell line is p53-deficient due to TP53 mutation and also harbors deletions in RB1, contributing to unchecked cell cycle progression and resistance to genotoxic stress. Notably, SCaBER strongly expresses EGFR, and activation of the MAPK/ERK and PI3K/AKT pathways is observed constitutively, even in the absence of exogenous growth factors.

The model lacks expression of luminal markers such as GATA3, FOXA1, uroplakin II, and CK20, and instead expresses high levels of CK5, CK14, and ΔNp63, consistent with basal lineage specification. SCaBER also expresses vimentin, fibronectin, and MMP-9, suggesting partial EMT and invasive potential. Its transcriptomic profile aligns closely with the basal-squamous subtype identified in TCGA bladder cancer classifications.

Characteristic	SCaBER Profile
Origin	Human bladder squamous cell carcinoma
TP53 Status	Mutated (non-functional)
RB1 Status	Homozygous deletion
EGFR Expression	Very high
Luminal Markers (GATA3, CK20)	Absent
Basal Markers (CK5, CK14, ΔNp63)	High
EMT Profile	Strong (vimentin+, MMP-9+, fibronectin+)
PI3K/AKT and MAPK Signaling	Constitutively active
Differentiation Type	Squamous/basal
Invasive Potential	High (in vitro and in vivo under certain conditions)

This aggressive molecular architecture makes SCaBER highly suitable for modeling resistance to standard therapies and for testing pathway-specific inhibitors in basal-bladder cancers.

In Vivo Model Development and Tumorigenicity

The SCaBER xenograft model forms tumors rapidly and reproducibly in immunodeficient mice, including athymic nude and NOD/SCID strains. Subcutaneous implantation of 5 × 10^6 to 1 × 10^7 cells in Matrigel yields tumor take rates >90%, with palpable masses developing within 7–10 days. Tumors exhibit exponential growth, typically reaching endpoint volumes of 1,200–1,500 mm³ within 21–28 days.

Tumors are compact, highly cellular, and non-metastatic in standard subcutaneous protocols, although invasion into surrounding dermal tissue can be observed in later stages. While orthotopic bladder implantation has been less commonly performed with SCaBER due to its non-urothelial lineage, studies using bladder wall injection have shown feasibility, particularly in modeling local invasion and squamous metaplasia.

The SCaBER xenograft is compatible with longitudinal tumor tracking and pharmacodynamic tissue analysis. Its rapid and aggressive kinetics are advantageous for testing therapies under time-constrained conditions or evaluating early biomarkers of drug response and resistance.

Request a Custom Quote for SCaBER Xenograft Model

Histopathology and Immunohistochemical Profile

SCaBER xenografts exhibit histological features consistent with poorly differentiated squamous carcinoma. Tumors display extensive cellular atypia, hyperchromatic nuclei, prominent nucleoli, and abundant cytoplasm with intercellular bridges and occasional keratinization. Necrosis is commonly observed in larger tumors, often with central cavitation.

Immunohistochemically, tumors express high levels of CK5/6, CK14, and ΔNp63, with diffuse nuclear staining for p63 indicating basal-like differentiation. EGFR is strongly expressed on the cell surface and throughout the tumor mass. Ki-67 labeling index exceeds 75%, reflecting the high proliferative capacity of the model.

In addition, SCaBER xenografts are E-cadherin–low, and express vimentin, MMP-9, and fibronectin, especially at invasive margins, supporting the EMT-competent phenotype. Tumor vasculature is abundant and evenly distributed, as shown by CD31 staining. The lack of GATA3, FOXA1, and uroplakin II confirms the non-luminal, non-differentiated state of the model.

Preclinical Applications and Drug Response

SCaBER xenografts are widely used to investigate therapeutic vulnerabilities in basal-squamous bladder cancers, especially those characterized by EGFR amplification and TP53/RB1 loss. The model is highly responsive to EGFR tyrosine kinase inhibitors such as erlotinib, afatinib, and dacomitinib, although resistance emerges rapidly via compensatory PI3K/AKT or EMT-related mechanisms. As such, SCaBER is frequently used for combination therapy studies involving EGFR inhibitors + MEK inhibitors, PI3K inhibitors, or HDAC inhibitors.

Because of its EMT plasticity and invasive profile, SCaBER is also suited for evaluating MMP inhibitors, TGF-β pathway antagonists, and epigenetic reprogramming agents. The model is valuable for testing compounds aimed at reversing mesenchymal traits or restoring epithelial adhesion, particularly in aggressive bladder tumors with squamous metaplasia or keratinization.

In addition, SCaBER serves as a tool for dissecting basal lineage specification, chromatin remodeling, and resistance to DNA-damaging therapies such as cisplatin, to which the model is variably resistant. It is frequently chosen for high-throughput screening of molecularly targeted therapies against p53-deficient, EGFR-overexpressing carcinomas.

Request This Model

To request the SCaBER xenograft model or explore its application in studies of basal bladder cancer, EMT modulation, EGFR pathway targeting, or p53-deficient therapeutic screening, please use the quote request form below. We offer technical consultation, timeline customization, and model integration services.

Request a Custom Quote for SCaBER Xenograft Model